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Masquelet method is an effective method that allows getting the consolidation of the bone in case of 
critical size bone loss. 
Keywords: Masquelet technique, bone defects, induced membrane technique.
180. ADHERENCE TO TYROSINE KINASE INHIBITORS TREATMENT IN 
PATIENTS WITH CHRONI C MYELOID LEUKEMIA: SINGLE INSTITUTION 
EXPERIENCE
Adrian-Stefan Chiuzan, Mihai Stanca
Scientific adviser: Smaranda Demian, University of Medicine and Pharmacy, Targu Mures, Romania
Introduction: Treatment adherence is an important element in the management of every chronic 
disease. For the patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors 
(TKI) the remarkable benefits brought by the medication may be significantly undermined by the patient 
low adherence to treatment. 
Materials and methods: We conducted a qualitative and observational study, which was 
performed between October 2015 and December 2015, on patients diagnosed with CML under treatment 
with TKI at I-st Medical Clinic-Hematology, Clinical Emergency County Hospital Targu Mures, 
Romania. The sampling of patients was simple-random, consisting of 32 patients with CML-chronic 
phase, >18 years old, with >12 months of treatment with TKI, median age was 55 years, 67.47% of the 
patients were males and 62.5% of the patients were treated with imatinib 400 mg/QD. Physician-reported 
adherence (observed adherence) was evaluated, for the last 3 months, using the Proportion of Days 
Covered (PDC) method and patient-reported adherence (experienced adherence) using a self-reporting 
questionnaire with 10 items regarding adherence to treatment; demographic data were collected too. The 
following statistical analysis was used: descriptive statistic, Fisher Exact test, unpaired t-test.
Results: PDC was <0.9 (low adherence) in 3 patients and 0.9-1 in 5 patients (medium adherence); 
Total lower adherence (low + medium) was 25%, patients being younger (p=0,044), but adherence was 
not correlated with gender, TKI treatment length, urban/rural place of living (p>0.05). 46.88% of the 
patients admit omission of doses, 73.33% of them attributing it to forgetfulness (33.33% rarely forgot, 
40% sometimes), the other 26.66% to medication adverse effects or to a sense of feeling sick.
Conclusion: PDC estimation of adherence was more optimistic compared to experienced 
adherence. Due to the unavoidable errors Associated with patient self-report, the rate of non-adherence 
is probably underestimated. Because the adherence to chronic medication in general and to TKI in 
particular is multifactorial, further quantitative, multiparameter and multicenter studies are necessary.
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